These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22170556)

  • 1. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.
    Ainai A; Tamura S; Suzuki T; Ito R; Asanuma H; Tanimoto T; Gomi Y; Manabe S; Ishikawa T; Okuno Y; Odagiri T; Tashiro M; Sata T; Kurata T; Hasegawa H
    J Med Virol; 2012 Feb; 84(2):336-44. PubMed ID: 22170556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
    Ainai A; Tamura S; Suzuki T; van Riet E; Ito R; Odagiri T; Tashiro M; Kurata T; Hasegawa H
    Hum Vaccin Immunother; 2013 Sep; 9(9):1962-70. PubMed ID: 23896606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
    Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
    Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
    Morokutti A; Muster T; Ferko B
    Vaccine; 2014 Apr; 32(17):1897-900. PubMed ID: 24560674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized mucosal response to intranasal live attenuated influenza vaccine in adults.
    Barría MI; Garrido JL; Stein C; Scher E; Ge Y; Engel SM; Kraus TA; Banach D; Moran TM
    J Infect Dis; 2013 Jan; 207(1):115-24. PubMed ID: 23087433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
    Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
    Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
    J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.
    Manenti A; Tete SM; Mohn KG; Jul-Larsen Å; Gianchecchi E; Montomoli E; Brokstad KA; Cox RJ
    Vaccine; 2017 Jan; 35(1):191-198. PubMed ID: 27789145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
    Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
    J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.
    Hauge S; Madhun A; Cox RJ; Haaheim LR
    Clin Vaccine Immunol; 2007 Aug; 14(8):978-83. PubMed ID: 17596426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
    Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.